Program Description
Patients with indolent lymphomas such as follicular and marginal zone lymphomas require long-term treatment with multiple therapies as these diseases are not curable. New agents and approved combinations for treatment of indolent lymphomas have the potential to improve quality of life for patients, help them achieve longer periods of remission, and mitigate financial burden. As cost of care and treatment burden is closely related to what line of therapy patients receive, pharmacists practicing on oncology care teams must be familiar with preferred and recommended therapy regimens. This activity will focus on the pharmacist’s role in treatment and management of follicular lymphoma and marginal zone lymphoma and considerations for optimizing resource utilization for these therapies.
Target audience: Oncology pharmacists, managed care pharmacists, and specialty pharmacists
Type of activity: Application
Release date: July 25, 2022
Expiration date: September 25, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine recent updates to current guidelines around the treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL), including the addition of CD-19-directed therapies and bispecific antibodies.
- Identify the safety and efficacy of newer therapies alongside current standard-of-care oral oncolytics to manage therapies for patients with FL and MZL.
- Explain costs associated with treatment of indolent lymphomas and considerations for development of utilization management tools.
Kelly Valla, PharmD, BCOP
Clinical Specialist, Lymphomas
Columbia, Maryland
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-302-L01-P. The activity is available for CE credit through September 25, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Kelly Valla, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Speaker’s Bureau: BeiGene
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms